1.
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
by Mullican, Shannon E
Nature medicine, 2017-10, Vol.23 (10), p.1150-1157
2.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
by le Roux, Carel W, Prof
The Lancet (British edition), 2017, Vol.389 (10077), p.1399-1409
3.
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
by Emmerson, Paul J
Nature medicine, 2017-10, Vol.23 (10), p.1215-1219
4.
Adipose lipid turnover and long-term changes in body weight
by Arner, P
Nature Medicine, 2019-09, Vol.25 (9), p.1385-1389
5.
Management of obesity
by Bray, George A, Prof
The Lancet (British edition), 2016, Vol.387 (10031), p.1947-1956
6.
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
by Clément, Karine
Nature medicine, 2018-05, Vol.24 (5), p.551-555
7.
Body Composition Changes After Very-Low-Calorie Ketogenic Diet in Obesity Evaluated by 3 Standardized Methods
by Gomez-Arbelaez, Diego
The journal of clinical endocrinology and metabolism, 2017-02, Vol.102 (2), p.488-498
8.
Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommendable?
by Brouns, Fred
European journal of nutrition, 2018-06, Vol.57 (4), p.1301-1312
9.
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand
by Yang, Linda
Nature medicine, 2017-10, Vol.23 (10), p.1158-1166
10.
Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study
Diabetologia, 2017-03-27, Vol.60 (6), p.980-988
11.
Executive function in weight loss and weight loss maintenance: a conceptual review and novel neuropsychological model of weight control
by Gettens, Katelyn M
Journal of behavioral medicine, 2017-02-03, Vol.40 (5), p.687-701
12.
A Metabolomic Signature of Acute Caloric Restriction
by Collet, Tinh-Hai
The journal of clinical endocrinology and metabolism, 2017-09-29, Vol.102 (12), p.4486-4495
13.
Management of obesity: improvement of health-care training and systems for prevention and care
by Dietz, William H, Dr
The Lancet (British edition), 2015, Vol.385 (9986), p.2521-2533
14.
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
by Ahern, Amy L, Dr
The Lancet (British edition), 2017, Vol.389 (10085), p.2214-2225
15.
Change in Weight and Body Mass Index Associated With All-Cause Mortality in Korea: A Nationwide Longitudinal Study
by Kim, Yang-Hyun
The journal of clinical endocrinology and metabolism, 2017-11, Vol.102 (11), p.4041-4050
16.
A circadian rhythm-related MTNR1B genetic variant modulates the effect of weight-loss diets on changes in adiposity and body composition: the POUNDS Lost trial
by Goni, Leticia
European journal of nutrition, 2018-03-07, Vol.58 (4), p.1381-1389
17.
Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance
by Abete, Itziar
Nutrition reviews, 2010-04, Vol.68 (4), p.214-231
18.
A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): a pragmatic randomised control...
by Hunt, Kate, Prof
The Lancet (British edition), 2014, Vol.383 (9924), p.1211-1221
19.
Moderate weight change following diabetes diagnosis and 10 year incidence of cardiovascular disease and mortality
by Strelitz, Jean
Diabetologia, 2019-05-07, Vol.62 (8), p.1391-1402
20.
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by Greenway, Frank L, Prof
The Lancet (British edition), 2010, Vol.376 (9741), p.595-605
